Pekin Hardy Strauss Inc. acquired a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 48,250 shares of the company’s stock, valued at approximately $541,000.
Several other large investors have also recently modified their holdings of CLPT. Essex Investment Management Co. LLC grew its position in ClearPoint Neuro by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 463,853 shares of the company’s stock worth $5,200,000 after acquiring an additional 1,267 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of ClearPoint Neuro by 562.6% in the second quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock worth $915,000 after purchasing an additional 144,088 shares during the last quarter. Legato Capital Management LLC grew its holdings in shares of ClearPoint Neuro by 21.6% in the second quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock worth $857,000 after purchasing an additional 28,227 shares during the last quarter. AWM Investment Company Inc. purchased a new position in shares of ClearPoint Neuro in the first quarter worth $894,000. Finally, Squarepoint Ops LLC bought a new stake in ClearPoint Neuro during the 2nd quarter valued at $549,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.
Analysts Set New Price Targets
Separately, Lake Street Capital boosted their price objective on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th.
ClearPoint Neuro Trading Up 6.8 %
NASDAQ CLPT opened at $11.84 on Monday. ClearPoint Neuro, Inc. has a fifty-two week low of $5.11 and a fifty-two week high of $14.13. The stock has a 50 day simple moving average of $11.91 and a two-hundred day simple moving average of $9.23.
About ClearPoint Neuro
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Recommended Stories
- Five stocks we like better than ClearPoint Neuro
- Canadian Penny Stocks: Can They Make You Rich?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- How to Read Stock Charts for Beginners
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What Are Some of the Best Large-Cap Stocks to Buy?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding CLPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ClearPoint Neuro, Inc. (NASDAQ:CLPT – Free Report).
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.